Reticulon-4 isoform A (Nogo-A)

Reticulon-4 isoform A, widely known as Nogo-A, is a transmembrane protein primarily expressed by oligodendrocytes in the central nervous system (CNS) where it acts as a potent inhibitor of axonal regeneration (UniProt Q9NQC3). It contains two distinct inhibitory domains, Amino-Nogo and Nogo-66, which interact with receptors such as NgR1 and S1PR2 to induce growth cone collapse and stabilize the myelin structure (PubMed: 10659854, 22995830). In clinical contexts, Nogo-A is a significant therapeutic target because its presence prevents the repair of damaged neural pathways following spinal cord injury or stroke (PubMed: 24553413). Research into Nogo-A inhibitors, including monoclonal antibodies like ozanezumab and decoy receptors like AXER-204, focuses on neutralizing these inhibitory signals to enhance neuroplasticity and functional recovery in patients with neurodegenerative diseases or CNS trauma (ClinicalTrials.gov: NCT01769079). Beyond its role in inhibition, Nogo-A also contributes to the maintenance of endoplasmic reticulum morphology and the regulation of synaptic strength (PubMed: 15685223).

Other names

Nogo-ARTN4-ANeurite outgrowth inhibitorNSPASYNI-250

Therapeutic agents such as monoclonal antibodies (e.g., ozanezumab) or decoy receptors (e.g., AXER-204) bind to and neutralize Nogo-A or its inhibitory domains (Nogo-66 and Amino-Nogo), preventing interaction with the Nogo receptor complex (NgR1/p75/LINGO-1) and S1PR2 to promote axonal regrowth and functional recovery (PubMed: 24553413, 22995830).